All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

insulin degludec 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	4960	844439-96-9

Description:

Molecule	Description
Synonyms: insulin degludec tresiba NN1250	insulin degludec is a long-acting basal human insulin analog for subcutaneous injection, differs from human insulin in that the amino acid threonine in position B30 has been omitted and a side-chain consisting of glutamic acid and a C16 fatty acid has been attached Molecular weight: 6104.04 Formula: C274H411N65O81S6 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 2356.52 ALOGS: ROTB: None

Drug dosage:

Dose	Unit	Route
40	U	P
40	U	P
40	U	P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
Sept. 25, 2015	FDA	NOVO NORDISK INC
Jan. 21, 2013	EMA
Sept. 28, 2012	PMDA	Novo Nordisk Pharma Ltd

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypoglycaemia	954.29	14.92	371	13730	69477	90544869
Diabetic ketoacidosis	477.22	14.92	169	13932	24238	90590108
Blood glucose increased	417.16	14.92	230	13871	95016	90519330
Blood glucose decreased	218.68	14.92	95	14006	23334	90591012
Diabetes mellitus inadequate control	175.13	14.92	76	14025	18608	90595738
Hyperglycaemia	156.62	14.92	98	14003	50872	90563474
Blood glucose fluctuation	129.67	14.92	43	14058	5040	90609306
Diabetic neuropathy	121.93	14.92	40	14061	4534	90609812
Hypoglycaemic coma	112.42	14.92	34	14067	2956	90611390
Heart sounds	98.82	14.92	25	14076	1119	90613227
Glycosylated haemoglobin increased	97.87	14.92	48	14053	15514	90598832
Prolonged expiration	96.48	14.92	25	14076	1232	90613114
Diabetic retinopathy	81.68	14.92	26	14075	2676	90611670
Sleep disorder due to a general medical condition	72.02	14.92	58	14043	44680	90569666
Hypoglycaemic unconsciousness	71.36	14.92	18	14083	796	90613550
Impaired gastric emptying	70.21	14.92	36	14065	12773	90601573
Depressive symptom	64.64	14.92	26	14075	5259	90609087
Euglycaemic diabetic ketoacidosis	60.63	14.92	26	14075	6175	90608171
Blood glucose abnormal	58.85	14.92	29	14072	9463	90604883
Respiration abnormal	57.46	14.92	27	14074	7936	90606410
Diabetes mellitus	57.13	14.92	60	14041	64815	90549531
Appetite disorder	56.91	14.92	28	14073	9105	90605241
Infusion related reaction	52.76	14.92	3	14098	416777	90197569
Scleroedema	51.32	14.92	10	14091	130	90614216
Stress	50.83	14.92	63	14038	81332	90533014
Rales	47.49	14.92	30	14071	15797	90598549
Suicide attempt	46.50	14.92	58	14043	75341	90539005
Hypoglycaemia unawareness	46.19	14.92	9	14092	117	90614229
Device failure	45.54	14.92	22	14079	6875	90607471
Intentional overdose	45.27	14.92	64	14037	93770	90520576
Ketoacidosis	43.57	14.92	20	14081	5575	90608771
Hypoglycaemic encephalopathy	42.45	14.92	10	14091	331	90614015
Joint abscess	39.60	14.92	10	14091	444	90613902
Acute kidney injury	39.04	14.92	124	13977	320263	90294083
Synovitis	37.18	14.92	4	14097	329748	90284598
Medical device site abscess	36.00	14.92	8	14093	203	90614143
Hospitalisation	35.46	14.92	68	14033	128032	90486314
Medical device site cellulitis	35.46	14.92	8	14093	218	90614128
Arthropathy	35.40	14.92	7	14094	366235	90248111
Ketosis	33.88	14.92	10	14091	799	90613547
Contraindicated product administered	33.39	14.92	5	14096	320134	90294212
Hypoacusis	32.40	14.92	30	14071	27820	90586526
Neuropathy peripheral	32.29	14.92	68	14033	136902	90477444
Retinopathy	31.88	14.92	14	14087	3520	90610826
Fear-related avoidance of activities	31.27	14.92	7	14094	184	90614162
Flank pain	31.09	14.92	25	14076	19197	90595149
Wound	30.99	14.92	5	14096	302975	90311371
Systemic lupus erythematosus	30.89	14.92	9	14092	361887	90252459
Treatment failure	28.96	14.92	6	14095	303922	90310424
Acute painful neuropathy of rapid glycaemic control	28.84	14.92	4	14097	3	90614343
Diabetic metabolic decompensation	28.77	14.92	11	14090	1946	90612400
Joint swelling	28.49	14.92	22	14079	503278	90111068
Hypoglycaemic seizure	28.25	14.92	8	14093	552	90613794
Carcinoid crisis	28.17	14.92	7	14094	291	90614055
Angina pectoris	27.19	14.92	32	14069	39128	90575218
Drug intolerance	26.05	14.92	19	14082	447572	90166774
Discomfort	24.96	14.92	6	14095	274329	90340017
Impaired healing	23.64	14.92	4	14097	234195	90380151
Dyspnoea exertional	23.31	14.92	41	14060	72247	90542099
Presbyopia	22.87	14.92	7	14094	633	90613713
Hypoglycaemia neonatal	22.78	14.92	8	14093	1114	90613232
Loss of personal independence in daily activities	22.68	14.92	59	14042	136046	90478300
Thirst decreased	22.29	14.92	6	14095	343	90614003
Type 1 diabetes mellitus	22.05	14.92	12	14089	4800	90609546
Productive cough	21.43	14.92	41	14060	77022	90537324
Metabolic acidosis	21.18	14.92	34	14067	55642	90558704
Muscle necrosis	20.97	14.92	7	14094	837	90613509
Helicobacter infection	20.56	14.92	5	14096	226845	90387501
Nasal congestion	20.33	14.92	42	14059	83372	90530974
Sleep disorder therapy	20.32	14.92	6	14095	480	90613866
Product dose omission issue	19.91	14.92	94	14007	291593	90322753
Depressed mood	19.55	14.92	31	14070	50191	90564155
Reperfusion arrhythmia	19.54	14.92	5	14096	234	90614112
Musculoskeletal stiffness	19.41	14.92	11	14090	296521	90317825
Diabetic nephropathy	19.39	14.92	8	14093	1726	90612620
Infective myositis	19.15	14.92	4	14097	75	90614271
Retinal degeneration	19.10	14.92	7	14094	1102	90613244
Analgesic therapy	18.40	14.92	6	14095	666	90613680
Abdominal discomfort	18.07	14.92	29	14072	477299	90137047
Drug ineffective	18.03	14.92	134	13967	1384164	89230182
Rheumatoid arthritis	17.91	14.92	18	14083	362596	90251750
Antacid therapy	17.73	14.92	6	14095	748	90613598
Anti-insulin antibody positive	17.69	14.92	4	14097	110	90614236
Appendicolith	17.67	14.92	6	14095	755	90613591
Incorrect dose administered by device	17.52	14.92	11	14090	5726	90608620
Tendon injury	17.37	14.92	8	14093	2245	90612101
Drug therapy	17.31	14.92	6	14095	803	90613543
Anticoagulant therapy	17.26	14.92	6	14095	811	90613535
Asthma	17.23	14.92	79	14022	242081	90372265
Therapeutic product effect decreased	17.18	14.92	11	14090	277560	90336786
Product prescribing error	16.70	14.92	22	14079	30123	90584223
Diabetic foot	16.48	14.92	7	14094	1624	90612722
Intestinal ulcer	16.28	14.92	7	14094	1672	90612674
Influenza	16.11	14.92	53	14048	139211	90475135
Inflammation	16.05	14.92	4	14097	178588	90435758
Haemorrhagic disorder	16.00	14.92	6	14095	1006	90613340
Palpitations	15.78	14.92	52	14049	136676	90477670
Injection site pain	15.73	14.92	61	14040	173638	90440708
Myopia	15.34	14.92	7	14094	1925	90612421
Insulin resistance	15.22	14.92	6	14095	1152	90613194
Erysipelas	15.12	14.92	12	14089	9040	90605306
Musculoskeletal pain	15.08	14.92	4	14097	171247	90443099
Pre-eclampsia	15.03	14.92	13	14088	11035	90603311

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	502.80	19.11	190	16029	13266	42591850
Hypoglycaemia	483.07	19.11	294	15925	59560	42545556
Appendicitis	434.07	19.11	193	16026	20420	42584696
Cardiogenic shock	358.26	19.11	202	16017	35438	42569678
Stress	305.53	19.11	197	16022	44015	42561101
Ascites	288.32	19.11	209	16010	56469	42548647
Ventricular fibrillation	268.64	19.11	158	16061	29965	42575151
Blood phosphorus increased	262.63	19.11	117	16102	12408	42592708
Abdominal distension	228.53	19.11	201	16018	71534	42533582
Blood glucose increased	194.72	19.11	186	16033	73513	42531603
Multiple organ dysfunction syndrome	184.19	19.11	205	16014	96830	42508286
Myasthenia gravis	182.65	19.11	99	16120	16038	42589078
Diabetic ketoacidosis	170.14	19.11	106	16113	22261	42582855
Hyponatraemia	168.38	19.11	200	16019	101262	42503854
Blood uric acid increased	166.60	19.11	92	16127	15455	42589661
General physical health deterioration	159.85	19.11	239	15980	151007	42454109
Hyperphosphataemia	150.55	19.11	81	16138	12923	42592193
Dry mouth	145.73	19.11	121	16098	39758	42565358
Blood cholesterol increased	136.65	19.11	99	16120	26642	42578474
Blood glucose decreased	127.74	19.11	75	16144	14144	42590972
Bacterial infection	119.71	19.11	93	16126	27786	42577330
Diabetes mellitus inadequate control	119.70	19.11	74	16145	15316	42589800
Hypophosphataemia	117.28	19.11	82	16137	20863	42584253
Sleep disorder therapy	115.07	19.11	55	16164	6839	42598277
Analgesic therapy	114.87	19.11	54	16165	6470	42598646
Iron deficiency	114.50	19.11	64	16155	10997	42594119
Neuralgia	113.27	19.11	87	16132	25560	42579556
Constipation	113.18	19.11	213	16006	162078	42443038
Incorrect route of product administration	112.97	19.11	85	16134	24220	42580896
Abdominal pain	110.01	19.11	231	15988	190240	42414876
Drug therapy	109.85	19.11	52	16167	6328	42598788
Vomiting	105.67	19.11	294	15925	289429	42315687
Sepsis	100.61	19.11	229	15990	199105	42406011
Hypoglycaemic unconsciousness	81.62	19.11	24	16195	760	42604356
Impaired gastric emptying	79.52	19.11	37	16182	4329	42600787
Swelling	73.02	19.11	97	16122	54788	42550328
Nausea	72.23	19.11	320	15899	396479	42208637
Glycosylated haemoglobin increased	64.06	19.11	47	16172	12877	42592239
Anticoagulant therapy	60.29	19.11	31	16188	4504	42600612
Euglycaemic diabetic ketoacidosis	59.25	19.11	33	16186	5627	42599489
Antacid therapy	59.14	19.11	31	16188	4686	42600430
Thrombosis	58.00	19.11	98	16121	68413	42536703
Activated partial thromboplastin time prolonged	57.51	19.11	48	16171	15855	42589261
Sleep disorder	56.42	19.11	80	16139	48015	42557101
Somnolence	56.03	19.11	148	16071	140957	42464159
Intentional product misuse	51.67	19.11	88	16131	61812	42543304
Bacteroides infection	50.48	19.11	23	16196	2564	42602552
Toxicity to various agents	49.62	19.11	13	16206	229123	42375993
Drug intolerance	47.97	19.11	99	16120	80325	42524791
Hyperglycaemia	46.17	19.11	71	16148	45788	42559328
End stage renal disease	45.92	19.11	43	16176	16515	42588601
Chronic obstructive pulmonary disease	45.30	19.11	84	16135	63030	42542086
Troponin increased	44.43	19.11	45	16174	19017	42586099
Aortic stenosis	43.78	19.11	32	16187	8713	42596403
Drug hypersensitivity	40.18	19.11	105	16114	99284	42505832
Ulcer	38.66	19.11	39	16180	16402	42588714
Hypoglycaemic encephalopathy	38.60	19.11	11	16208	311	42604805
Onychoclasis	37.79	19.11	19	16200	2633	42602483
Hypoglycaemia unawareness	36.25	19.11	9	16210	147	42604969
Hypoglycaemic seizure	36.21	19.11	11	16208	390	42604726
Total lung capacity decreased	35.16	19.11	20	16199	3550	42601566
Blood calcium increased	33.67	19.11	27	16192	8427	42596689
Disease progression	33.35	19.11	7	16212	143649	42461467
Hyperlipidaemia	33.27	19.11	41	16178	21475	42583641
Hypoglycaemic coma	31.48	19.11	17	16202	2727	42602389
Anion gap abnormal	31.14	19.11	10	16209	427	42604689
Bronchopulmonary aspergillosis allergic	30.49	19.11	20	16199	4578	42600538
Blood glucose fluctuation	28.12	19.11	19	16200	4568	42600548
Gout	27.62	19.11	43	16176	28012	42577104
Drug ineffective	27.59	19.11	135	16084	630062	41975054
Pulmonary embolism	27.56	19.11	104	16115	119508	42485608
Blood test abnormal	27.43	19.11	29	16190	12877	42592239
Henoch-Schonlein purpura nephritis	26.33	19.11	5	16214	20	42605096
Hypotension	26.09	19.11	36	16183	257595	42347521
Congenital hiatus hernia	25.19	19.11	20	16199	6154	42598962
Pneumonia	24.38	19.11	81	16138	422068	42183048
Neutropenia	24.34	19.11	24	16195	199407	42405709
Lung opacity	24.01	19.11	19	16200	5818	42599298
Pyrexia	23.87	19.11	74	16145	393968	42211148
Condition aggravated	23.13	19.11	174	16045	260580	42344536
Neuropathy peripheral	22.99	19.11	88	16131	101765	42503351
Diabetic neuropathy	21.47	19.11	16	16203	4486	42600630
Drug interaction	20.88	19.11	44	16175	266955	42338161
Tachycardia	19.57	19.11	7	16212	101080	42504036

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypoglycaemia	1097.54	14.60	547	26864	115557	110446331
Appendicolith	591.30	14.60	195	27216	14060	110547828
Diabetic ketoacidosis	499.12	14.60	232	27179	41826	110520062
Appendicitis	476.65	14.60	200	27211	28264	110533624
Blood glucose increased	422.42	14.60	311	27100	132185	110429703
Cardiogenic shock	365.06	14.60	208	27203	57130	110504758
Stress	355.47	14.60	256	27155	105092	110456796
Ventricular fibrillation	301.54	14.60	164	27247	41149	110520739
Blood phosphorus increased	301.16	14.60	123	27288	16217	110545671
Ascites	295.95	14.60	218	27193	92590	110469298
Diabetes mellitus inadequate control	250.59	14.60	130	27281	29645	110532243
Myasthenia gravis	219.43	14.60	107	27304	21404	110540484
Abdominal distension	199.26	14.60	231	27180	174872	110387016
Multiple organ dysfunction syndrome	196.29	14.60	214	27197	151496	110410392
Blood uric acid increased	192.72	14.60	98	27313	21431	110540457
Hyperphosphataemia	183.81	14.60	87	27324	16294	110545594
Blood glucose decreased	182.29	14.60	105	27306	29383	110532505
Hyperglycaemia	165.67	14.60	150	27261	84940	110476948
Sleep disorder therapy	154.09	14.60	61	27350	7410	110554478
Analgesic therapy	152.08	14.60	60	27351	7224	110554664
Hyponatraemia	146.52	14.60	222	27189	217431	110344457
Drug therapy	145.05	14.60	58	27353	7233	110554655
Impaired gastric emptying	138.28	14.60	67	27344	13208	110548680
Diabetic neuropathy	133.44	14.60	54	27357	6945	110554943
Iron deficiency	128.28	14.60	71	27340	18405	110543483
Hypoglycaemic coma	127.64	14.60	49	27362	5484	110556404
Hypophosphataemia	126.55	14.60	87	27324	33095	110528793
Blood glucose fluctuation	125.14	14.60	53	27358	7645	110554243
Glycosylated haemoglobin increased	124.78	14.60	76	27335	23543	110538345
Bacterial infection	124.29	14.60	98	27313	45938	110515950
Hypoglycaemic unconsciousness	122.18	14.60	33	27378	1187	110560701
Euglycaemic diabetic ketoacidosis	122.09	14.60	59	27352	11564	110550324
Neuralgia	119.83	14.60	98	27313	48380	110513508
Sepsis	118.70	14.60	255	27156	327091	110234797
Constipation	116.55	14.60	267	27144	357519	110204369
Heart sounds	91.80	14.60	26	27385	1117	110560771
Incorrect route of product administration	89.15	14.60	94	27317	63967	110497921
Anticoagulant therapy	87.44	14.60	37	27374	5324	110556564
Antacid therapy	86.63	14.60	37	27374	5447	110556441
Prolonged expiration	83.95	14.60	26	27385	1526	110560362
General physical health deterioration	79.67	14.60	259	27152	425036	110136852
Hypoglycaemic encephalopathy	79.52	14.60	21	27390	692	110561196
Hypoglycaemia unawareness	77.46	14.60	17	27394	249	110561639
Thrombosis	76.11	14.60	113	27298	108549	110453339
Diabetic retinopathy	73.15	14.60	29	27382	3535	110558353
Abdominal pain	72.64	14.60	285	27126	512704	110049184
Activated partial thromboplastin time prolonged	72.24	14.60	53	27358	22315	110539573
Infusion related reaction	66.86	14.60	8	27403	381154	110180734
Neuropathy peripheral	65.27	14.60	140	27271	179137	110382751
End stage renal disease	65.13	14.60	49	27362	21424	110540464
Aortic stenosis	63.83	14.60	40	27371	13019	110548869
Troponin increased	62.91	14.60	55	27356	29711	110532177
Bacteroides infection	57.29	14.60	23	27388	2896	110558992
Chronic obstructive pulmonary disease	56.57	14.60	99	27312	109059	110452829
Dry mouth	56.14	14.60	141	27270	199807	110362081
Vomiting	55.73	14.60	401	27010	910274	109651614
Toxicity to various agents	55.24	14.60	25	27386	480530	110081358
Ketoacidosis	54.66	14.60	33	27378	10054	110551834
Hyperlipidaemia	54.19	14.60	55	27356	35793	110526095
Synovitis	52.68	14.60	4	27407	274088	110287800
Intentional product misuse	52.10	14.60	107	27304	132797	110429091
Blood glucose abnormal	51.93	14.60	35	27376	12881	110549007
Gout	51.48	14.60	54	27357	36512	110525376
Hypoglycaemic seizure	51.38	14.60	16	27395	956	110560932
Arthropathy	50.50	14.60	6	27405	287516	110274372
Treatment failure	48.16	14.60	6	27405	277228	110284660
Appetite disorder	47.94	14.60	30	27381	9739	110552149
Somnolence	46.76	14.60	171	27240	297278	110264610
Joint swelling	46.45	14.60	26	27385	442819	110119069
Blood calcium increased	45.68	14.60	37	27374	18003	110543885
Nausea	45.27	14.60	486	26925	1235204	109326684
Scleroedema	44.92	14.60	10	27401	157	110561731
Diabetic metabolic decompensation	44.68	14.60	21	27390	3868	110558020
Diabetes mellitus	43.74	14.60	84	27327	99297	110462591
Total lung capacity decreased	43.07	14.60	25	27386	7089	110554799
Respiration abnormal	42.87	14.60	28	27383	9781	110552107
Sleep disorder due to a general medical condition	42.07	14.60	58	27353	52054	110509834
Depressive symptom	41.70	14.60	26	27385	8388	110553500
Rales	41.17	14.60	40	27371	24699	110537189
Therapeutic product effect decreased	38.51	14.60	7	27404	244309	110317579
Suicide attempt	37.90	14.60	81	27330	103313	110458575
Systemic lupus erythematosus	36.58	14.60	9	27402	254329	110307559
Drug ineffective	35.73	14.60	226	27185	1520314	109041574
Congenital hiatus hernia	35.27	14.60	21	27390	6238	110555650
Ulcer	33.32	14.60	47	27364	43069	110518819
Intentional overdose	32.63	14.60	89	27322	132412	110429476
Pulmonary embolism	32.59	14.60	122	27289	214352	110347536
Medical device site abscess	32.33	14.60	8	27403	202	110561686
Completed suicide	32.19	14.60	10	27401	242371	110319517
Bronchopulmonary aspergillosis allergic	31.90	14.60	22	27389	8404	110553484
Sinusitis	31.70	14.60	17	27394	296671	110265217
Inflammation	31.63	14.60	5	27406	193233	110368655
Medical device site cellulitis	31.58	14.60	8	27403	223	110561665
Rheumatoid arthritis	30.81	14.60	18	27393	299595	110262293
Joint abscess	30.70	14.60	10	27401	691	110561197
Fear-related avoidance of activities	30.39	14.60	7	27404	129	110561759
Discomfort	30.10	14.60	8	27403	214699	110347189
Lung opacity	29.72	14.60	24	27387	11628	110550260
Blood cholesterol increased	29.66	14.60	107	27304	184678	110377210
Anion gap abnormal	28.98	14.60	10	27401	826	110561062
Pancreatic carcinoma	28.49	14.60	26	27385	14846	110547042
Impaired healing	28.20	14.60	7	27404	196710	110365178
Drug abuse	28.13	14.60	5	27406	177406	110384482
Onychoclasis	27.64	14.60	19	27392	7218	110554670
Disease progression	27.54	14.60	13	27398	244021	110317867
Helicobacter infection	27.01	14.60	6	27405	181871	110380017
Liver injury	26.74	14.60	3	27408	150410	110411478
Blood test abnormal	26.45	14.60	34	27377	28520	110533368
Tachycardia	25.69	14.60	12	27399	226633	110335255
Intentional product use issue	25.33	14.60	15	27396	247891	110313997
Musculoskeletal pain	25.31	14.60	7	27404	183016	110378872
Neutropenia	24.76	14.60	34	27377	374586	110187302
Hypersensitivity	24.43	14.60	39	27372	403959	110157929
Pain	24.42	14.60	138	27273	954817	109607071
Diabetic foot	23.76	14.60	14	27397	4081	110557807
Arthralgia	23.13	14.60	107	27304	779525	109782363
Abdominal discomfort	22.90	14.60	39	27372	393819	110168069
Stomatitis	22.85	14.60	20	27391	270222	110291666
Wound	22.83	14.60	15	27396	234422	110327466
Fibromyalgia	22.78	14.60	7	27404	170902	110390986
Retinopathy	22.74	14.60	14	27397	4415	110557473
Contraindicated product administered	22.70	14.60	17	27394	248250	110313638
Hypoacusis	22.37	14.60	35	27376	35156	110526732
Oedematous pancreatitis	22.35	14.60	10	27401	1644	110560244
Thrombocytopenia	21.74	14.60	33	27378	348852	110213036
Alopecia	21.31	14.60	36	27375	364717	110197171
C-reactive protein increased	21.14	14.60	14	27397	217905	110343983
Hypotension	20.65	14.60	64	27347	523785	110038103
Carcinoid crisis	20.65	14.60	7	27404	548	110561340
Anti-insulin antibody positive	20.60	14.60	6	27405	285	110561603
Flank pain	20.58	14.60	27	27384	23103	110538785
Acute painful neuropathy of rapid glycaemic control	20.54	14.60	4	27407	31	110561857
Hepatic enzyme increased	20.33	14.60	30	27381	320862	110241026
Ill-defined disorder	19.90	14.60	7	27404	156846	110405042
Migraine	19.59	14.60	9	27402	171643	110390245
Sleep disorder	19.43	14.60	99	27312	198545	110363343
Thirst decreased	19.16	14.60	6	27405	365	110561523
Type 2 diabetes mellitus	19.15	14.60	10	27401	177222	110384666
Benign prostatic hyperplasia	18.95	14.60	23	27388	18211	110543677
Device failure	18.71	14.60	15	27396	7192	110554696
Ketosis	18.71	14.60	9	27402	1745	110560143
Blister	17.84	14.60	18	27393	227358	110334530
Diabetic foot infection	17.47	14.60	7	27404	877	110561011
Diabetic wound	17.40	14.60	4	27407	73	110561815
Psoriatic arthropathy	17.32	14.60	14	27397	196747	110365141
Incorrect dose administered by device	17.30	14.60	14	27397	6800	110555088
Therapy non-responder	16.81	14.60	9	27402	157298	110404590
Leukopenia	16.67	14.60	8	27403	148783	110413105
Hyperinsulinaemic hypoglycaemia	16.25	14.60	5	27406	287	110561601
Product use issue	16.22	14.60	33	27378	311662	110250226
White blood cell count decreased	15.99	14.60	20	27391	229370	110332518
Reperfusion arrhythmia	15.89	14.60	5	27406	309	110561579
Renal impairment	15.77	14.60	90	27321	188355	110373533
Pharyngeal perforation	15.68	14.60	3	27408	21	110561867
Contusion	15.59	14.60	21	27390	233340	110328548
Diabetic nephropathy	15.30	14.60	10	27401	3498	110558390
Presbyopia	15.12	14.60	6	27405	733	110561155
Dyspepsia	15.12	14.60	15	27396	190950	110370938
Nasal congestion	14.99	14.60	56	27355	98226	110463662
Micturition urgency	14.84	14.60	21	27390	19299	110542589

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A10AD06	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES INSULINS AND ANALOGUES Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
ATC	A10AE06	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES INSULINS AND ANALOGUES Insulins and analogues for injection, long-acting
ATC	A10AE56	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES INSULINS AND ANALOGUES Insulins and analogues for injection, long-acting
FDA CS	M0011417	Insulin
FDA EPC	N0000175453	Insulin Analog
FDA EPC	N0000175944	Insulin
CHEBI has role	CHEBI:22587	antiviral agent
CHEBI has role	CHEBI:35469	antidepressant
CHEBI has role	CHEBI:35476	antipsychotic agent
CHEBI has role	CHEBI:35480	analgesic
CHEBI has role	CHEBI:35526	hypoglycemic agent
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:35674	antihypertensive agent
CHEBI has role	CHEBI:35705	immunosuppressive agent
CHEBI has role	CHEBI:35821	anticholesteremic drug
CHEBI has role	CHEBI:39456	antiglaucoma drug
CHEBI has role	CHEBI:48407	antiparkinson drug
CHEBI has role	CHEBI:50864	insulin-sensitizing drug
CHEBI has role	CHEBI:66981	ophthalmology drug
CHEBI has role	CHEBI:73336	vulnerary
CHEBI has role	CHEBI:74518	anti-obesity agent
CHEBI has role	CHEBI:76916	hyperglycemic agent
CHEBI has role	CHEBI:145947	antiatherosclerotic agent
CHEBI has role	CHEBI:231911	renoprotective agent

Related Drugs by ATC class:

A10AD Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting 5 drugs

insulin aspartinsulin beefinsulin humaninsulin lisproinsulin pork

A10AE Insulins and analogues for injection, long-acting 9 drugs

insulin beefinsulin detemirinsulin glargineinsulin humaninsulin icodecinsulin porkliraglutidelixisenatidesemaglutide

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Diabetes mellitus	indication	73211009	DOID:9351

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Insulin receptor	Kinase	P06213	INSR_HUMAN	AGONIST				DRUG LABEL	DRUG LABEL

External reference:

ID	Source
D09727	KEGG_DRUG
4017559	VANDF
4017569	VANDF
4019786	VANDF
4035011	VANDF
CHEBI:752911	CHEBI
CHEMBL2107869	ChEMBL_ID
C571886	MESH_SUPPLEMENTAL_RECORD_UI
DB09564	DRUGBANK_ID
1670007	RXNORM
236826	MMSL
29260	MMSL
361472	MMSL
366445	MMSL
4885	MMSL
4886	MMSL
d00262	MMSL
d04369	MMSL
d08054	MMSL
000869	NDDF
000870	NDDF
006518	NDDF
015340	NDDF
126210001	SNOMEDCT_US
417423002	SNOMEDCT_US
420609005	SNOMEDCT_US
710281005	SNOMEDCT_US
715774000	SNOMEDCT_US
96367001	SNOMEDCT_US
C3491971	UMLSCUI
C0795635	UMLSCUI
DB00030	DRUGBANK_ID
9170	INN_ID
118984462	PUBCHEM_CID
118984375	PUBCHEM_CID
54Q18076QB	UNII
5186	INN_ID
CHEBI:5931	CHEBI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Tresiba	HUMAN PRESCRIPTION DRUG LABEL	1	0169-2550	INJECTION, SOLUTION	200 U	SUBCUTANEOUS	BLA	27 sections
Tresiba	HUMAN PRESCRIPTION DRUG LABEL	1	0169-2660	INJECTION, SOLUTION	100 U	SUBCUTANEOUS	BLA	27 sections
Tresiba	HUMAN PRESCRIPTION DRUG LABEL	1	0169-2662	INJECTION, SOLUTION	100 U	SUBCUTANEOUS	BLA	27 sections
Xultophy 100/3.6	HUMAN PRESCRIPTION DRUG LABEL	2	0169-2911	INJECTION, SOLUTION	100 [iU]	SUBCUTANEOUS	BLA	27 sections
Xultophy 100/3.6	HUMAN PRESCRIPTION DRUG LABEL	2	0169-2911	INJECTION, SOLUTION	100 [iU]	SUBCUTANEOUS	BLA	27 sections
Tresiba	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3491	INJECTION, SOLUTION	200 U	SUBCUTANEOUS	BLA	28 sections
TRESIBA	HUMAN PRESCRIPTION DRUG LABEL	1	50090-7094	INJECTION, SOLUTION	200 U	SUBCUTANEOUS	BLA	27 sections
Insulin Degludec	HUMAN PRESCRIPTION DRUG LABEL	1	50090-7175	INJECTION, SOLUTION	200 U	SUBCUTANEOUS	BLA	27 sections
Insulin Degludec	HUMAN PRESCRIPTION DRUG LABEL	1	50090-7176	INJECTION, SOLUTION	100 U	SUBCUTANEOUS	BLA	27 sections
Insulin Degludec	HUMAN PRESCRIPTION DRUG LABEL	1	73070-400	INJECTION, SOLUTION	100 U	SUBCUTANEOUS	BLA	27 sections
Insulin Degludec	HUMAN PRESCRIPTION DRUG LABEL	1	73070-403	INJECTION, SOLUTION	100 U	SUBCUTANEOUS	BLA	27 sections
Insulin Degludec	HUMAN PRESCRIPTION DRUG LABEL	1	73070-503	INJECTION, SOLUTION	200 U	SUBCUTANEOUS	BLA	27 sections